• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PNVL3.SA
Share

Dimed S.A. Distribuidora de Medicamentos Stocks

R$ 11.01Last Updated 13.11.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

R$ 309.02M

R$ 11.01
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Eldorado do Sul, Brazil, Dimed S.A. Distribuidora de Medicamentos is a Brazilian company that supplies a wide range of goods, including pharmaceuticals, fragrances, personal care products, cosmetics, and dermocosmetics. Its business model encompasses both retail and wholesale operations. The company distributes its merchandise through logistical hubs situated in the states of Rio Grande do Sul, Paraná, and Espírito Santo. Furthermore, it boasts an extensive retail network of 517 stores, located across Rio Grande do Sul, Santa Catarina, Paraná, and São Paulo. Before April 2000, the company was known as Panvel S.A. Drogarias e Farmacias.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, under

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of PNVL3.SA is 17.8 and suggests 60.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.11.2026 03:32

SpaceX has successfully caught Starship with its capture tower for the first time. What does this mean for the stock?

14.11.2026 17:01

What's New in Small-Cap Stocks: The Forbes Ranking, Oklo's Plans for Meta, and Ceco's Record

14.11.2026 13:01

Is There Life After Huang? The Rise of Anthropic, and the AI Rally in the Clouds

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026